Open AccessThe performance of 18F-PSMA PET/CT in the detection of prostate cancer: a systematic review and meta-analysis
Author(s) -
Zhiqiang Qin,
Guangtao Pan,
Zheng Xu,
Hao Wang,
Luwei Xu,
Ru Jia
Publication year - 2022
Publication title -
asian journal of andrology/asian journal of andrology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.701
H-Index - 74
eISSN - 1745-7262
pISSN - 1008-682X
DOI - 10.4103/aja202162
Subject(s) - prostate cancer , medicine , glutamate carboxypeptidase ii , meta analysis , confidence interval , positron emission tomography , nuclear medicine , prostate , positron emission tomography computed tomography , prostate specific antigen , oncology , cancer
This paper presents a meta-analysis regarding the detection rate (DR) of fluorine-18 ( 18 F)-labeled prostate-specific membrane antigen positron emission tomography/computed tomography (PSMA PET/CT) in the management of patients with prostate cancer (PCa). Relevant studies regarding 18 F-PSMA PET/CT in the management of PCa published until June 1, 2021, were electronically searched in online databases including EMBASE, PubMed, and Web of Science. The primary outcome was the DR of 18 F-PSMA PET/CT in managing PCa patients, while the secondary outcome was the DR of 18 F-PSMA PET/CT according to Gleason scores and serum prostate-specific antigen (PSA) level. The pooled DR was calculated on a per-patient basis, with pooled odd ratios and 95% confidence intervals (CIs). In total, 17 observational studies evaluating 1019 patients with PCa met the inclusion criteria. The DR of 18 F-PSMA PET/CT was 0.83 (95% CI: 0.78-0.88), in the random-effects model. Subsequently, the analysis of DR of 18 F-PSMA PET/CT in PCa patients using Gleason score (≤7 vs ≥8), showed a significant difference in PCa patients. Based on the above results, the higher Gleason score of PCa patients, the higher DR of 18 F-PSMA PET/CT. The DR of 18 F-PSMA PET/CT in PCa was 0.57 for PSA <0.5 ng ml -1 ; 0.75 for PSA ≥0.5 ng ml -1 and <1.0 ng ml -1 ; 0.93 for PSA ≥1.0 ng ml -1 and <2.0 ng ml -1 ; and 0.95 for PSA ≥2.0 ng ml -1 . Therefore, the significant diagnostic value was found in terms of the DR of 18 F-PSMA PET/CT in managing PCa patients and was associated with Gleason score and serum PSA level.